EcoDrugPlus

Glycogen Synthase Kinase 3 Alpha

Ensembl ID : ENSPKIG00000016961
Gene Symbol: GSK3A
3 Cross references
186 Possible Orthologues:

Glycogen Synthase Kinase 3 Beta

Ensembl ID : ENSPKIG00000009029
Gene Symbol: GSK3B
4 Cross references
222 Possible Orthologues:

Glycogen Synthase Kinase-3 Beta

Ensembl ID : ENSPKIG00000010801
Gene Symbol: LOC111852698
4 Cross references
221 Possible Orthologues:

Gonadotropin Releasing Hormone Receptor

Ensembl ID : ENSPKIG00000001282
Gene Symbol: GNRHR
3 Cross references
87 Possible Orthologues:

Gonadotropin Releasing Hormone Receptor 1

Ensembl ID : ENSPKIG00000012641
Gene Symbol: GNRHR1
1 Cross references
202 Possible Orthologues:

Granzyme A-Like

Ensembl ID : ENSPKIG00000022453
Gene Symbol: LOC111839252
2 Cross references
1316 Possible Orthologues:

Granzyme K-Like

Ensembl ID : ENSPKIG00000022437
Gene Symbol: LOC111839253
2 Cross references
2 Possible Orthologues:

Growth Hormone Releasing Hormone Receptor

Ensembl ID : ENSPKIG00000003111
Gene Symbol: GHRHR
2 Cross references
191 Possible Orthologues:

Growth Hormone Secretagogue Receptor

Ensembl ID : ENSPKIG00000021028
Gene Symbol: GHSR
3 Cross references
199 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSPKIG00000018212
Gene Symbol: GUCY1A1
3 Cross references
201 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSPKIG00000023593
Gene Symbol: GUCY1A2
2 Cross references
203 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSPKIG00000018265
Gene Symbol: GUCY1B1
3 Cross references
210 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).